Santarus, Inc. (SNTS) / 3.13$

3 Kommentare / 0 neu
10.05.2010 21:00
#1
Bild des Benutzers LoadeT
Offline
Kommentare: 701
Santarus, Inc. (SNTS) / 3.13$

Aktueller Kurs: http://www.google.com/finance?q=NASDAQ:SNTS

Dieses Biotech Unternehmen soll massiv unterbewertet sein nach einem "Crash" wegen Patentstreitigkeiten..

Form 10K:

http://ir.santarus.com/secfiling.cfm?filingID=950123-10-20667

ZEGERID® (omeprazole/sodium bicarbonate) is the Only Immediate-Release Oral proton pump inhibitor (PPI) providing continued acid control for patients with gastroesophagael reflux disease (GERD).

ZEGERID is indicated for:

•Short-term treatment (4-8 weeks) of active duodenal ulcer

•Short-term treatment (4-8 weeks) of active benign gastric ulcer

•Heartburn and other symptoms associated with GERD

•Short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed in endoscopy

•Maintenance of healing of erosive esophagitis (controlled studies do not extend beyond 12 months)

•Reduction of risk of upper GI bleeding in critically ill patients (powder for oral suspension only)

ZEGERID Powder for Oral Suspension 40 mg/1680 mg is the only FDA approved PPI for reduction of risk of upper GI bleeding in critically ill patients. Use beyond 14 days has not been evaluated.

AnhangGröße
Image icon fdanda_snts_690.jpg33.09 KB
Image icon chart_snts_169.png22.51 KB
Image icon snts_pipeline_110.jpg69.89 KB
Aufklappen
01.08.2011 21:13
Bild des Benutzers sharewatch
Offline
Kommentare: 865
Santarus, Inc. (SNTS) / 3.13$

Nachgeladen 3.14

27.07.2011 20:46
Bild des Benutzers sharewatch
Offline
Kommentare: 865
Santarus, Inc. (SNTS) / 3.13$

In 3.24